In this respect, a sequential resistance mechanism-specific algorithm, analogous to those in place and further developing for EGFR+ or ALK+ NSCLC, could represent an ambitious but optimal goal [82,83]. This evidence concerns the gene ALK and non-small cell lung carcinoma.